LifeTech Scientific Corporation
先健科技公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Aortic Arch Stent Graft System Obtained Official Registration Approval from the China NMPA

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 14 May 2025, the Aortic Arch Stent Graft System (the "**Product**") jointly developed by the National Centre for Cardiovascular Diseases, Professor Shu Chang of Fuwai Hospital, the Chinese Academy of Medical Sciences and the Group, obtained official registration approval from the China National Medical Products Administration ("**NMPA**"). The Product is the first stent graft system approved by NMPA to explicitly aim at aortic arch branch reconstruction by using fenestration technique and is applicable to endovascular repair and treatment for Stanford Type B aortic dissection patients. It is able to repair aortic lesion vessels while precisely maintaining left subclavian artery blood perfusion, providing off-the-shelf device solution for patients with insufficient landing zone or left subclavian artery involvement.

Aortic Arch Stent Graft System consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System, and it entered the "Special Examination and Approval Procedure for Innovative Medical Devices" in 2022. According to the pre-market clinical study information from the "prospective, multicenter, single-arm objective performance criteria" conducted by Professor Shu Chang as the principal researcher (involving a total of 120 subjects), the

intraoperative immediate technical success rate was 97.5%, the one-year postoperative branch vessel patency rate was 99.1%, the one-year postoperative type III endoleak rate was only 1.8%, and there were no stent migration-related adverse events. These fully prove the safety and effectiveness of the innovative product in the treatment of Stanford Type B dissection lesions of the left subclavian artery.

Fenestration technique is one of the mainstream techniques for reconstructing aortic arch branches in thoracic endovascular aortic repair (TEVAR). International guidelines, including those from the European Society for Vascular Surgery (ESVS) in 2017, the Japanese Circulation Society (JCS) in 2020, and the Society of Thoracic Surgeons/American Association for Thoracic Surgery (STS/AATS) in 2022, explicitly recommend fenestration technique as a precise treatment option for patients with insufficient landing zone or left subclavian artery involvement.

The Group possesses independent intellectual property rights of the Product, which is expected to provide a complete, safe and effective endovascular repair solution for the treatment of aortic dissection lesions involving the aortic arch. This solution is entirely interventional, with anticipated advantages of less trauma, simpler operation and easier adaptation.

The approval and launch of the Product further enriches the Company's portfolio in the peripheral vascular intervention field. As the commercialization process continues to progress, the Company will provide an integrated solution for endovascular aortic arch reconstruction that is more flexible, more comprehensive, safer and more effective, and simpler to operate. Furthermore, in collaboration with industry experts, the Company will advance the research, development, and launch of additional device products that are urgently needed in clinical practice, thereby driving the Group's development in the field of medical devices and benefiting a wide range of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 15 May 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.